NECLIFE — Nectar Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹3.02bn
- IN₹8.57bn
- IN₹16.70bn
- 19
- 84
- 15
- 30
Annual cashflow statement for Nectar Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -595 | 341 | -424 | 183 | -1,615 |
| Depreciation | |||||
| Non-Cash Items | 648 | 685 | 390 | 768 | 766 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -443 | -645 | 779 | 689 | 1,920 |
| Change in Other Assets | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 214 | 950 | 1,337 | 2,247 | 1,694 |
| Capital Expenditures | -312 | -250 | -301 | -294 | -438 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 26.2 | 416 | 818 | 124 | 18.6 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -286 | 166 | 517 | -170 | -419 |
| Financing Cash Flow Items | -1,120 | -788 | -795 | -871 | -746 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 115 | -1,194 | -1,856 | -2,054 | -1,281 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 42.5 | -77.3 | -2.28 | 22.3 | -5.84 |